Morgan Stanley Maintains Overweight on Arcus Biosciences, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Arcus Biosciences (NYSE:RCUS) but lowered the price target from $40 to $38.
August 08, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Arcus Biosciences but lowered the price target from $40 to $38.
The news is directly related to Arcus Biosciences. While the Overweight rating is maintained, indicating a positive outlook, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100